Ocular Therapeutix resubmits NDA for ocular pain relief implant

This article was originally published here

Ocular Therapeutix (NSDQ:OCUL) said today that it resubmitted a new drug application for its Dextenza ocular pain relief implant to the FDA.

The Bedford, Mass.-based company noted that the resubmitted application aims to address manufacturing deficiencies highlighted by the FDA last year when the agency rejected Dextenza for the second time.

Get the full story at our sister site, Drug Delivery Business News.

The post Ocular Therapeutix resubmits NDA for ocular pain relief implant appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply